Contemporary management of chronic lymphocytic leukemia: Optimal management of chronic lymphocytic leukemia (CLL) is evolving rapidly with multiple approvals of several targeted agents that offer highly active and well-tolerated options for care. The availability of these novel agents is changing our approach to diagnosis, classification, and therapeutic decisions. This educational session will discuss the latest advances both in the clinic and the laboratory with the goal of providing personalized therapy for patients with CLL.
Dr. Jacqueline Barrientos will discuss strategies in the management of patients with CLL with a particular emphasis on understanding the optimal treatment algorithm or sequencing of therapies based on a patient’s clinical presentation, disease biology, and treatment history.
Dr. Susan O’Brien will review evidence-based treatment approaches for the use of the recently approved targeted agents along with their potential side effects.Emerging treatment options that are still in clinical development will also be described.
Dr. Barbara Eichhorst will define relevant prognostic markers (genetic and biochemical) that predict the prognosis of individual patients with CLL. The clinical implications of prognostic testing in the era of novel targeted agents will be discussed.